info@seagull-health.com
SeagullHealth
语言:
search
new
How effective is Capivasertib?
501
Article source: Seagull Pharmacy
Jul 04, 2025

Capivasertib is a potential targeted therapy that provides a new treatment option for patients with specific types of breast CA. The drug has excellent therapeutic effects and is trusted by patients. This article will discuss in depth the therapeutic effects of Capivasertib and the key precautions when using the drug.

How effective is Capivasertib?

Since its approval by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA), Capivasertib has been marketed in many countries and regions around the world for the treatment of specific types of breast diseases. Its therapeutic effect has attracted much attention and has become a hot topic among patients and the medical community.

The clinical treatment effect is relatively good

Capivasertib has shown excellent therapeutic effects in the treatment of patients with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast disease.

In particular, in FDA-approved trials, Capivasertib combined with fulvestrant can effectively delay disease progression and improve the quality of life of patients with PIK3CA/AKT1/PTEN changes.

The scope of application is gradually expanding

With the deepening of research, the scope of application of Capivasertib is also gradually expanding. On November 16, 2023, the US FDA once again approved Capivasertib for the treatment of a wider range of patients with HR-positive, HER2-negative locally advanced or metastatic breast diseases, which further confirmed its value in the treatment of breast diseases.

Capivasertib has shown excellent therapeutic effects in the treatment of specific types of breast diseases, bringing new treatment options and hope to patients. However, there are individual differences in the treatment effect. Patients should fully understand their own condition and drug properties before use, and work with doctors to develop personalized treatment plans.

Precautions for the use of Capivasertib

Although Capivasertib has achieved relatively outstanding results in the treatment of breast diseases, the precautions during its use are equally important. Understanding and following these precautions can ensure the safety and effectiveness of the medication and avoid potential risks.

Usage and dosage must be strictly followed

The recommended dosage and administration method of Capivasertib must be strictly followed by the doctor. The recommended dose of Capivasertib combined with fulvestrant is usually 400 mg, taken orally twice a day (about 12 hours apart) for 4 days, followed by a 3-day break. Patients should pay close attention to the time and dosage of medication during medication to avoid missing or overdosing.

Use with caution in special populations

Capivasertib should be used with caution in special populations such as pregnant women, lactating women, children, and men and women of reproductive potential. Pregnant women taking Capivasertib may cause harm to the fetus, so pregnant women and women of reproductive potential should consult a doctor before use to understand the potential risks of the drug and take effective contraceptive measures. In addition, the safety and effectiveness of Capivasertib for children have not been confirmed, so it is not recommended.

Monitor adverse reactions and deal with them in time

Capivasertib may cause a series of adverse reactions during treatment, including diarrhea, adverse skin reactions, and increased blood sugar. Patients should pay close attention to their physical condition during the use of the drug. If the above adverse reactions occur, they should inform the doctor in time and take appropriate treatment measures. The doctor will adjust the treatment plan according to the patient's specific situation to ensure the safety and effectiveness of the medication.

Capivasertib is an innovative therapeutic drug that brings new hope to patients with breast diseases, but the precautions during its use are equally important. Patients should fully understand the characteristics of the drug before use, follow the doctor's instructions, strictly control the usage and dosage, and pay close attention to their physical condition.

Note: For internal discussion among medical personnel only. For specific medication, please consult the attending physician. Drug information may change over time. For the latest information, we recommend adding a medical consultant or consulting for free online.
Capivasertib(Truqap)
Capivasertib(Truqap)
Used in combination with fulvestrant for the treatment of HR-positive,...
WeChat Scan
Free Inquiry
Recommended Articles
How much does Capivasertib cost per box?
Capivasertib is a drug used to treat a specific type of breast cancer, and its price and purchase method have attracted much attention. This article will provide detailed information about Capiva...
Where to buy Capivasertib
Capivasertib is a potential targeted therapy that provides a new treatment option for patients with certain types of breast CA. Before using Capivasertib, patients usually need to undergo genetic...
Capivasertib instructions: indications, efficacy and effects, dosage, side effects, precautions
Capivasertib(Truqap) is a targeted therapy drug mainly used for patients with specific types of breast lesions. Its indications are based on genetic test results, and the applicable population mu...
Indications of Capivasertib
Capivasertib (also known as Truqap) is an innovative drug that is widely recognized internationally, especially in the treatment of specific types of breast diseases. However, its use is not with...
Side effects of Capivasertib(Truqap)
Capivasertib inhibits the activity of the PI3K/AKT signaling pathway, thereby controlling the proliferation and survival of diseased cells and delaying the progression of the disease. So, does Ca...
A brief introduction to Capivasertib
Capivasertib(Truqap) is a new type of targeted therapy for patients with specific types of advanced or metastatic breast lesions. The drug works by inhibiting the PI3K/AKT signaling pathway, prov...
Instructions for use and indications of Indian Capivasertib
Capivasertib(Truqap) is a targeted therapy for patients with specific breast lesions and should be used strictly in accordance with the doctor's instructions. Correct use of the drug can impr...
Indications for Pirtobrutinib
Pirtobrutinib is a drug used to treat certain types of lymphoma and leukemia. It is mainly used for patients who have not responded well to other treatments or have relapsed. This article will ex...
Related Articles
Side Effects of Capivasertib
Capivasertib is a next-generation AKT kinase inhibitor. Used in combination with fulvestrant, it treats HR-positive, HER2-negative advanced breast cancer harboring PIK3CA/AKT1/PTEN mutations. While de...
What Are the Precautions for Capivasertib Administration?
Capivasertib is a kinase inhibitor. It is used in combination with fulvestrant for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer harboring PIK3CA/AKT1/PTEN gene muta...
Dosage and Administration of Capivasertib
Capivasertib is a novel kinase inhibitor that received its first approval in the United States in 2023. As a precision therapy targeting specific gene mutations, it has demonstrated favorable efficacy...
What Are the Indications of Capivasertib?
Capivasertib is a kinase inhibitor developed by AstraZeneca, which was first approved for marketing in the United States in 2023. When used in combination with fulvestrant, this medication is indicate...
What Are the Purchase Channels for Capivasertib?
Capivasertib is an AKT kinase inhibitor, providing a new treatment option for patients with HR-positive, HER2-negative advanced breast cancer. As a prescription medication, understanding its standardi...
How to Use Capivasertib
Capivasertib is an AKT kinase inhibitor that was approved for marketing in the United States in 2023. It is indicated for the treatment of locally advanced or metastatic breast cancer that is hormone ...
How to Use Capivasertib
Capivasertib is an AKT kinase inhibitor that was approved for marketing in the United States in 2023. It is indicated for the treatment of locally advanced or metastatic breast cancer that is hormone ...
What Are the Side Effects of Capivasertib?
Capivasertib, when used in combination with fulvestrant, is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative,...
New Drugs
Infigratinib(Truseltiq)
Infigratinib(Truseltiq)
Treatment of previously treated, unresectable locally advanced or metastatic...
Opicapone(Ongentys)
Opicapone(Ongentys)
Adjunctive treatment to levodopa/carbidopa for reducing "off" episodes in...
Deflazacort(Emflaza)
Deflazacort(Emflaza)
Treatment of Duchenne muscular dystrophy (DMD) in patients aged 2 years and...
Faricimab-svoa(Vabysmo)
Faricimab-svoa(Vabysmo)
Treatment of neovascular age-related macular degeneration, diabetic macular...
Counselling Service
Global Drug Search
Clinical Research Recruitment
Overseas Medical Treatment
Remote Consultations
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Submit
Business
  • Core products
  • Antitumor drugs
  • General drug
  • Antiviral drugs
  • Biological agents
Contact Us 
  • mailbox:info@lucius.la
Welcome to consult
ucius Pharmaceuticals (Lao) Co.,Ltd All rights reserved